Malignancy brain metastasis is a common event that negatively impacts the survival and quality of life of patients. Different sites and numbers of intracranial metastases can bring about different symptoms, the most common of which include nausea and vomiting, and unsteadiness. Magnetic resonance imaging (MRI) is the most widespread means of brain metastases diagnosis, while the availability of new MRI sequences, functional imaging techniques, and new contrast agents will facilitate the detection of microscopic intracranial metastases. However, there is still a lack of effective early detection methods for meningeal metastases, which often exhibit resistance to multiple treatments and are associated with rapid disease progression. Overall, there is great heterogeneity in the prognosis of brain metastases, depending not only on the variabilities of the neoplasm itself but also on the therapeutic choice and optimization. Brain metastases require a combination of systemic and local treatments, among which local treatments are surgery, whole brain radiotherapy, and stereotactic radiotherapy (SBRT). Previous studies suggested that SBRT could achieve higher local control rates and ensure that patients only suffer from a small amount of memory or emotional impairment compared to whole brain radiotherapy, but a high dose of SBRT entailed refractory radiation-related necrosis.
Targeted therapies have also gained much ground in the treatment of brain metastases, with third generation TKI having higher intracranial drug concentrations and showing better therapeutic response and duration of remission as compared with first generation EGFR-TKI. Monoclonal antibodies to VEGFR also have a better value in alleviating symptoms associated with cerebral edema. With the advent of immunotherapy, tremendous advances have occurred in the treatment of brain metastases from the group of non-EGFR, ALK-sensitive mutations, leading the original effective treatment paradigm needs to be further updated and validated. Therefore, we are calling for manuscripts from the following areas:
1. The latest mechanisms of tumor brain metastasis.
2. Optimization of radiotherapy modalities for brain metastases
3. Advances in the treatment of radiation brain injury
4. Efficacy and safety assessment of new drugs in brain metastasis
5. Novel treatment modalities for therapy-resistant and rapidly progressive meningeal metastases
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
Malignancy brain metastasis is a common event that negatively impacts the survival and quality of life of patients. Different sites and numbers of intracranial metastases can bring about different symptoms, the most common of which include nausea and vomiting, and unsteadiness. Magnetic resonance imaging (MRI) is the most widespread means of brain metastases diagnosis, while the availability of new MRI sequences, functional imaging techniques, and new contrast agents will facilitate the detection of microscopic intracranial metastases. However, there is still a lack of effective early detection methods for meningeal metastases, which often exhibit resistance to multiple treatments and are associated with rapid disease progression. Overall, there is great heterogeneity in the prognosis of brain metastases, depending not only on the variabilities of the neoplasm itself but also on the therapeutic choice and optimization. Brain metastases require a combination of systemic and local treatments, among which local treatments are surgery, whole brain radiotherapy, and stereotactic radiotherapy (SBRT). Previous studies suggested that SBRT could achieve higher local control rates and ensure that patients only suffer from a small amount of memory or emotional impairment compared to whole brain radiotherapy, but a high dose of SBRT entailed refractory radiation-related necrosis.
Targeted therapies have also gained much ground in the treatment of brain metastases, with third generation TKI having higher intracranial drug concentrations and showing better therapeutic response and duration of remission as compared with first generation EGFR-TKI. Monoclonal antibodies to VEGFR also have a better value in alleviating symptoms associated with cerebral edema. With the advent of immunotherapy, tremendous advances have occurred in the treatment of brain metastases from the group of non-EGFR, ALK-sensitive mutations, leading the original effective treatment paradigm needs to be further updated and validated. Therefore, we are calling for manuscripts from the following areas:
1. The latest mechanisms of tumor brain metastasis.
2. Optimization of radiotherapy modalities for brain metastases
3. Advances in the treatment of radiation brain injury
4. Efficacy and safety assessment of new drugs in brain metastasis
5. Novel treatment modalities for therapy-resistant and rapidly progressive meningeal metastases
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
